Skip to main content
Clinical Trials/NCT02690129
NCT02690129
Unknown
Not Applicable

Vaginal Progesterone for Treatment of Threatened Miscarriage; Randomized Clinical Trial

Omar Mamdouh Shaaban1 site in 1 country290 target enrollmentFebruary 2016

Overview

Phase
Not Applicable
Intervention
Vaginal Progesteron
Conditions
Threatened Miscarriage
Sponsor
Omar Mamdouh Shaaban
Enrollment
290
Locations
1
Primary Endpoint
Miscarriage rate up to 28 weeks of gestation
Last Updated
10 years ago

Overview

Brief Summary

The purpose of the study is to assess the efficacy of vaginal micronized progesterone in the treatment of threatened miscarriage. All eligible pregnant women will be randomized to either receive vaginal progesterone or no treatment.Evaluation will be two weeks after intervention, then every 4 weeks up to 28 weeks gestation or termination of pregnancy.

Registry
clinicaltrials.gov
Start Date
February 2016
End Date
February 2018
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
Omar Mamdouh Shaaban
Responsible Party
Sponsor Investigator
Principal Investigator

Omar Mamdouh Shaaban

Clinical Professor

Assiut University

Eligibility Criteria

Inclusion Criteria

  • Pregnant with gestational age less than 24 weeks
  • Presented by bleeding with or without pain
  • Single viable fetus (confirmed by Ultrasound examination)
  • Accepting to have vaginal medication

Exclusion Criteria

  • Currently under medication for any chronic diseases (DM, thyroid, liver, renal, cardiac and autoimmune disease).
  • Hypersensitivity to progesterone
  • Any documented congenital fetal anomaly in the current pregnancy
  • Women received hormonal treatment in the current pregnancy
  • Patients conceived via ART

Arms & Interventions

Group I (Progesterone Group)

Complete bed rest as an in/or out- patient, according to patient's preference for first 48-72 hours. * Vaginal progesterone treatment as single daily dose of natural micronized progesterone (Prontogest ® 200 mg) at bedtime for 15 days. * If needed, a pain killer as Indomethacin 50 mg/ rectally twice daily up to control of uterine colic . * Complete abstaining from sexual activity or strenuous effort. Additionally, Rh-ve women with established viable fetuses and continue bleeding will be given a shot of anti-D immunoglobulin 300 ugm/IM ; after 12 weeks' gestation or if undergo surgical evacuation.

Intervention: Vaginal Progesteron

Group II ( Control group)

Will follow the same plan of management without progesterone support.

Intervention: Vaginal Progesteron

Outcomes

Primary Outcomes

Miscarriage rate up to 28 weeks of gestation

Time Frame: Completed 28th week

Secondary Outcomes

  • Gestational age at delivery or termination of pregnancy(Number of completed weeks at the time of delivery)

Study Sites (1)

Loading locations...

Similar Trials